Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A.

Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30907-7. doi: 10.1016/j.ygyno.2018.05.020. [Epub ahead of print]

PMID:
29807697
2.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

3.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

4.

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A; Australian Ovarian Cancer Study Group.

Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23.

PMID:
28646021
5.

Our Faustian pact with the digital world.

McNeil CM, Harnett PR.

Lancet Oncol. 2017 Feb;18(2):171-172. doi: 10.1016/S1470-2045(17)30005-0. No abstract available.

PMID:
28214405
6.

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL; Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A.

Gynecol Oncol. 2016 Sep;142(3):458-64. doi: 10.1016/j.ygyno.2016.06.023. Epub 2016 Jul 18.

PMID:
27444035
7.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS).

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

8.

Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital.

Gupta S, Taylor N, Selvakumar D, Harnett PR, Wilcken N, Lee CI.

Intern Med J. 2014 Dec;44(12a):1235-9. doi: 10.1111/imj.12565.

PMID:
25169081
9.

Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.

Ojaimi S, Harnett PR, Fulcher DA.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):105-6. doi: 10.1016/j.jaip.2013.08.009. Epub 2013 Oct 17. No abstract available.

PMID:
24565780
10.

Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis.

Lei Y, Henderson BR, Emmanuel C, Harnett PR, deFazio A.

Oncogene. 2015 Jan 22;34(4):485-95. doi: 10.1038/onc.2013.566. Epub 2014 Feb 17.

PMID:
24531715
11.

Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.

Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, Byth K, Stuart K, Clarke JL, Thomas L.

Eur J Cancer. 2013 Nov;49(16):3396-403. doi: 10.1016/j.ejca.2013.06.046. Epub 2013 Aug 9.

PMID:
23937961
12.

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study.

Cancer Res. 2012 Aug 15;72(16):4060-73.

13.

Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.

Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, Clarke JL, Thomas L.

Eur Heart J Cardiovasc Imaging. 2013 Mar;14(3):228-34. doi: 10.1093/ehjci/jes139. Epub 2012 Jul 10.

PMID:
22782955
14.

Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.

Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, Clarke J, Thomas L.

Eur J Echocardiogr. 2011 Dec;12(12):945-52. doi: 10.1093/ejechocard/jer187. Epub 2011 Oct 1.

PMID:
21965152
15.

Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.

Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J; Australian Ovarian Cancer Study Group, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, Harnett PR, deFazio A.

PLoS One. 2011 Mar 15;6(3):e17617. doi: 10.1371/journal.pone.0017617.

16.

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.

Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.

Clin Cancer Res. 2008 Nov 1;14(21):6924-32. doi: 10.1158/1078-0432.CCR-07-5189.

17.

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.

Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G.

Clin Cancer Res. 2008 Sep 1;14(17):5594-601. doi: 10.1158/1078-0432.CCR-08-0606. Erratum in: Clin Cancer Res. 2012 Jan 1;18(1):319-20.

18.

Rupture of the intra-articular portion of the long head of the biceps associated with a symptomatic os acromiale.

Harnett PR, Ahrens PM, Gadikoppula SM.

Int J Shoulder Surg. 2008 Jul;2(3):56-8. doi: 10.4103/0973-6042.42578.

19.

Managing quality in cancer services: why improvement isn't easy.

Sorensen R, Lloyd AJ, Van Kemenade C, Harnett PR.

Aust Health Rev. 2005 Nov;29(4):406-15.

PMID:
16255704
20.

MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.

Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, Defazio A.

Gynecol Oncol. 2006 Feb;100(2):239-46. Epub 2005 Oct 5.

PMID:
16213010
21.

Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.

Balleine RL, Earls PJ, Webster LR, Mote PA, deFazio A, Harnett PR, Clarke CL.

Int J Gynecol Pathol. 2004 Apr;23(2):138-44.

PMID:
15084842
22.

"But doctor, what have I got to lose...?".

Harnett PR, Moynihan TJ.

J Clin Oncol. 2003 May 1;21(9 Suppl):27s-29s. No abstract available.

PMID:
12743184
23.

Scientists and clinicians test their metal-back to the future with platinum compounds.

Guminski AD, Harnett PR, deFazio A.

Lancet Oncol. 2002 May;3(5):312-8. Review.

PMID:
12067809
25.

"But doctor, what have i got to lose...?".

Harnett PR, Moynihan TJ.

J Clin Oncol. 2001 Jul 1;19(13):3294-6. No abstract available.

PMID:
11432900
26.

Should doctors wear white coats?

Harnett PR.

Med J Aust. 2001 Apr 2;174(7):343-4.

PMID:
11346107
27.

A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis.

King MT, Hall JP, Harnett PR.

Med J Aust. 2001 Mar 19;174(6):312; author reply 312-3. No abstract available.

PMID:
11297131
28.

Home or hospital? An evaluation of the costs, preferences, and outcomes of domiciliary chemotherapy.

King MT, Hall J, Caleo S, Gurney HP, Harnett PR.

Int J Health Serv. 2000;30(3):557-79.

PMID:
11109181
29.

Integrated multimodality therapy for embryonal rhabdomyosarcoma of the lower genital tract in postpubertal females.

Hahlin M, Jaworski RC, Wain GV, Harnett PR, Neesham D, Bull C.

Gynecol Oncol. 1998 Jul;70(1):141-6. Review.

PMID:
9698493
30.

Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines.

Segelov E, Mann G, deFazio A, Harnett PR.

Mutat Res. 1998 Jun;407(3):243-52.

PMID:
9653450
31.

Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy.

Currow DC, Findlay M, Cox K, Harnett PR.

Eur J Cancer. 1996 Dec;32A(13):2357-9.

PMID:
9038622
33.

Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary.

Della-Fiorentina SA, Jaworski RC, Crandon AJ, Harnett PR.

Aust N Z J Surg. 1996 Feb;66(2):124-5.

PMID:
8602811
35.

Persisting elevation of alpha-fetoprotein after chemotherapy for germ cell tumour--not always due to viable malignancy?

Shannon JA, Donnellan MJ, Friedlander ML, Harnett PR.

Eur J Cancer. 1995 Sep;31A(10):1722. No abstract available.

PMID:
7488439
36.

Euthanasia: attitudes and practices of medical practitioners.

Harnett PR.

Med J Aust. 1994 Nov 7;161(9):572. No abstract available.

PMID:
7968765
37.

Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma.

Jones SL, Hickson ID, Harris AL, Harnett PR.

Int J Cancer. 1994 Nov 1;59(3):388-93.

PMID:
7927947
38.

Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines.

Ireland CM, Pittman SM, Jones SL, Harnett PR.

Anticancer Res. 1994 Nov-Dec;14(6B):2397-403.

PMID:
7872659
39.

Heterogeneous repair of platinum-DNA adducts by protein extracts from mammalian tissues.

Jones SL, Harnett PR.

Biochem Pharmacol. 1994 Oct 18;48(8):1662-5.

PMID:
7980633
40.

Vertebral osteomyelitis in advanced breast cancer.

Goldrick A, Harnett PR.

Aust N Z J Med. 1993 Aug;23(4):406. No abstract available.

PMID:
8240155
41.
42.

Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. A marker of neural crest origins?

Harnett PR, Kearsley JH, Hayward NK, Dracopoli NC, Kefford RF.

Cancer Genet Cytogenet. 1991 Jul 1;54(1):109-13.

PMID:
1676609
43.

Method of extracting DNA from fine needle aspirates of human solid tumors for Southern blot analysis.

Harnett PR, Greenberg ML, Tattersall MH, Kefford RF.

Anal Quant Cytol Histol. 1989 Dec;11(6):375-8.

PMID:
2557850
44.

Cisplatin plus VP 16-213 in advanced ovarian carcinoma.

Harnett PR, Bell DR, Hillcoat BL, Woods RL, Levi JA, Rome RM, Campbell JC, Tattersall MH.

Gynecol Oncol. 1988 Jun;30(2):159-62.

PMID:
3371739
45.

Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer.

Harnett PR, Tattersall MH, Coates AS, van Couten R, Forbes J.

Eur J Cancer Clin Oncol. 1987 Nov;23(11):1601-5.

PMID:
3428331
46.

Orbital metastasis from prostatic carcinoma.

Harnett PR, Raghavan D, Langdon P, Duval P.

Br J Urol. 1987 Jun;59(6):591-2. No abstract available.

PMID:
3690191
47.

Aminoglutethimide in advanced prostatic carcinoma.

Harnett PR, Raghavan D, Caterson I, Pearson B, Watt H, Teriana N, Coates A, Coorey G.

Br J Urol. 1987 Apr;59(4):323-7.

PMID:
3555688
48.

Drug resistance in clinical practice: patterns of treatment failure in advanced breast and ovarian cancer.

Harnett PR, Kirsten F, Tattersall MH.

J Clin Oncol. 1986 Jun;4(6):952-7.

PMID:
3519884
49.

Drug resistance in the clinical situation.

Tattersall MH, Harnett PR.

Prog Clin Biol Res. 1986;223:151-9. No abstract available.

PMID:
3809197

Supplemental Content

Loading ...
Support Center